ArticleCHEST pulmonary2025
Epidemiology and Clinical Outcomes of Cardiac Arrhythmias in Pulmonary Arterial Hypertension.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Catheter Ablation in Atrial Fibrillation Patients With Pulmonary Hypertension.Pacing and clinical electrophysiology : PACE · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac arrhythmias can exacerbate symptoms and potentially lead to death in patients with pulmonary hypertension. However, there is limited evidence regarding the impact of cardiac arrhythmias in patients with pulmonary arterial hypertension (PAH). Research Question: What are the prevalence, incidence, and impact of arrhythmias in patients with PAH? Study Design and Methods: In a retrospective cohort study including 512 patients with PAH from 2001 to 2021 at 3 Mayo Clinic sites, demographic data at PAH diagnosis and clinical outcomes over a 10-year period were collected. The patients with PAH were categorized into 3 groups based on arrhythmic onset: (1) patients with arrhythmia before PAH diagnosis, (2) patients diagnosed with arrhythmia during PAH follow-up, and (3) patients without arrhythmia during PAH follow-up. Survival outcomes were analyzed using multivariable Cox proportional hazards regression, adjusted with the REVEAL 2.0 risk score. Results: Among the 512 patients with PAH (mean age, 56.1 years; 81.8% female), the prevalence of cardiac arrhythmias at PAH diagnosis was 10.5%, consisting of atrial fibrillation (7%), atrial flutter (2%), and supraventricular tachycardia (0.8%). The cumulative incidences of new-onset arrhythmias at 1, 5, and 10 years were 6%, 18%, and 29%, respectively. Patients with arrhythmia diagnosed before and after PAH diagnosis exhibited significantly higher all-cause mortality rates with adjusted hazard ratio of 2.06 (95% CI, 1.36-3.12) and 1.57 (95% CI, 1.17-2.20), respectively. Similarly, both arrhythmic groups demonstrated shorter median time to the first all-cause hospitalization (9.5 and 15.9 vs 21.2 months) and a higher number of all-cause hospitalizations (0.38 and 0.64 vs 0.10 times per year) compared with the nonarrhythmic group. Interpretation: Our results demonstrate that cardiac arrhythmias can develop in nearly one-third of patients with PAH within 10 years of PAH diagnosis and independently contribute to increased hospitalization frequency and mortality, in addition to the current REVEAL 2.0 risk score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.